However, the double positive charge at the physiological pH precludes a complete absorption, as showed by
preliminary pharmacokinetic studies.
Not exact matches
An Open - Label, Multicenter Phase I Study to Characterize the Safety, Tolerability,
Preliminary Anti-Tumor Activity,
Pharmacokinetics and Maximum Tolerated Dose of BAY 1251152 in Patients with Advanced Hematological Malignancies
A Multi-arm, Phase Ib, Open - Label, Multicentre Study to Assess the Safety, Tolerability,
Pharmacokinetics and
Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm + Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)